Management of type 2 diabetes: summary of updated NICE guidance
- PMID: 18535074
- PMCID: PMC2413390
- DOI: 10.1136/bmj.39560.442095.AD
Management of type 2 diabetes: summary of updated NICE guidance
Conflict of interest statement
Competing interests: All authors were members of the Guideline Development Group for the NICE guideline (PH the clinical lead, JM the chair, JD the lead systematic reviewer, and CT the project manager). Institutions associated with PH have received funding from nearly all pharmaceutical and diagnostics companies in connection with his research, educational, consultation, and development activities.
Comment in
-
Commentary: controversies in NICE guidance on management of type 2 diabetes.BMJ. 2008 Jun 7;336(7656):1308-9. doi: 10.1136/bmj.39581.495069.AD. BMJ. 2008. PMID: 18535075 Free PMC article. Review. No abstract available.
-
How does their approach to type 2 diabetes differ from that of the ADA?J Fam Pract. 2008 Sep;57(9):575. J Fam Pract. 2008. PMID: 18800445 No abstract available.
References
-
- International Diabetes Federation. Diabetes atlas 3rd ed. Brussels: International Diabetes Federation, 2006
-
- World Health Organization. Diabetes fact sheet (312). Geneva: World Health Organization, 2006. www.who.int/mediacentre/factsheets/fs312/en/
-
- National Institute for Health and Clinical Excellence. The management of type 2 diabetes (update). (Clinical guideline 66.) London: NICE, 2008. www.nice.org.uk/CG66
-
- National Institute for Health and Clinical Excellence. Ezetimibe for the treatment of primary (heterozygous familial and non-familial) hypercholesterolaemia (Clinical guideline TA132.) London: NICE, 2007. www.nice.org.uk/TA132
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical